John, Mike & Tom's <b>Wild World of Stocks</b> Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wlheatmoon who wrote (2622)	12/11/2001 10:03:08 PM
From: John Pitera	Read Replies (1) of 2850

NMPS has actually been moving a bit on announcement of a test that's more effective than the PSA for prostate cancer detection. biz.yahoo.com Monday December 10, 12:06 pm Eastern Time Press Release SOURCE: Matritech New Data Report Matritech's NMP48 Prostate Cancer Blood Test More Accurate than PSA NMP48 Test Could Reduce Unnecessary Biopsies NEWTON, Mass.--(BW HealthWire)--Dec. 10, 2001--A new blood test for the detection of prostate cancer developed by Matritech Inc. (NASDAQ: NMPS - news) correctly identified men with benign prostate disease (BPH) as negative for prostate cancer. These results are a significant improvement over the widely used prostate specific antigen (PSA) test, which often produces false-positive results for men with BPH. Matritech presented the NMP48(TM) prostate cancer test results at the New Discoveries in Prostate Cancer Biology and Treatment meeting, hosted by the American Association for Cancer Research. All blood samples used in the testing were provided by the Urology Department at The Johns Hopkins Hospital. ``The discovery of the NMP48 protein and the resulting test should significantly improve the process for diagnosing prostate cancer,'' said Matritech's senior protein chemist John J. Hlavaty, Ph.D, who leads the Matritech discovery team. ``PSA, the current test, often incorrectly appears positive in men with benign disease because the PSA test is not cancer-specific. These men must then endure invasive testing, including biopsy of the prostate, which is a painful and expensive procedure. It appears that NMP48 may reduce these unnecessary and expensive procedures.'' Blood specimens from 15 men with BPH were tested. PSA results were sufficiently elevated for 12 of these men to indicate the possibility of prostate cancer. Matritech's NMP48 test correctly identified 14 of the 15 men who did not have prostate cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next